Retifanlimab (Zynyz)
Immunotherapy · Approved since 2023
Description
Retifanlimab is a humanized monoclonal antibody that functions as a PD-1 (programmed death-1) immune checkpoint inhibitor used in colorectal cancer treatment. In CRC, it is primarily utilized for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, as indicated by mutations in MLH1, MSH2, MSH6, or PMS2 genes. The drug works by blocking the PD-1 receptor on T-cells, thereby preventing cancer cells from evading immune system detection and destruction. Retifanlimab has also been explored in combination regimens with other immunotherapeutic agents for metastatic colorectal cancer.
Mechanism of Action
Retifanlimab binds to the PD-1 receptor on activated T-lymphocytes, blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2. This blockade prevents the inhibitory signals that normally suppress T-cell activation, allowing the immune system to maintain its anti-tumor response. By removing this immune checkpoint brake, retifanlimab enables enhanced T-cell proliferation and cytotoxic activity against cancer cells.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Zynyz |
| Category | Immunotherapy |
 Status | FDA Approved |
 EMA Status | Not submitted to EMA |
 Spain Access | Not available |
| Administration | IV |
| Year Approved | 2023 |
| Clinical Trials | 5 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.